Mechanisms of Abeta Sequestration in AD

AD 中 Abeta 隔离的机制

• 批准号: 6774530
• 负责人: YASUJI MATSUOKA
• 金额: $ 12.61万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-01 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6774530
• 关键词: Alzheimer' s disease; aging; amyloid proteins; blood brain barrier; cerebrospinal fluid; conformation; enzyme linked immunosorbent assay; genetically modified animals; high performance liquid chromatography; immunocytochemistry; laboratory mouse; mass spectrometry; memory; memory disorders; neurosciences; protein binding; protein protein interaction

DESCRIPTION (provided by applicant): PA-00-019 Mentored Research Scientist Development Award (K01) "Mechanisms of the Abeta sequestration in AD" The candidate, Yasuji Matsuoka, PhD, is a junior researcher with considerable experience in neuroscience research in Alzheimer's disease (AD). In order to become a fully independent translational neuroscientist in AD and other neurodegenerative diseases, an additional supervised training period is critical. The candidate is eager to expand his knowledge and techniques in both clinical and basic aspects of therapeutic research. Dr. Paul Aisen (Professor of Neurology and Medicine, and Director of the Memory Disorders Program at Georgetown University), will be the primary mentor for training in drug development for AD. Drs. Karen Gale (Professor of Pharmacology, Georgetown University) and Karen Duff (Associate Professor, Nathan Kline Institute / New York University) will be co-mentors to provide training in behavioral analysis using transgenic models of Alzheimer's disease. Additional consultants will provide expertise in basic research into neurodegeneration (Dr. Mattson), medicinal chemistry (Dr. Kozikowski) and neuroimaging (Dr. Fricke) Georgetown University Medical Center offers a stimulating scientific and clinical environment. The five year career development plan aims to: 1) provide the candidate a strong understanding and background in clinical drug development; 2) improve and extend his research experience and knowledge in behavioral analysis of AD mouse models; 3) assure ethical conduct in both clinical and basic research using human subjects and animals. The primary research goal of this proposal is the elucidation of a promising, novel therapeutic approach to AD, "Abeta sequestration". The candidate has demonstrated that brain Aa can be altered using non-immune amyloid-binding compounds. The research studies proposed will investigate the pools and conformations of Aa that can be influenced by peripheral binding compounds, the ideal structure of such compounds, and blood-brain barrier transport of Abeta.

描述（由申请人提供）：PA-00-019指导的研究科学家发展奖（K01）“广告中Abeta固结的机制” 候选人Yasuji Matsuoka博士是一名初级研究员，在阿尔茨海默氏病（AD）方面具有丰富的神经科学研究经验。为了成为AD和其他神经退行性疾病中完全独立的转化神经科学家，额外的监督训练期至关重要。候选人渴望在治疗研究的临床和基本方面扩展他的知识和技术。 Paul Aisen博士（神经和医学教授，乔治敦大学的记忆障碍计划主任）将成为AD药物开发培训的主要导师。博士。 Karen Gale（乔治敦大学药理学教授）和Karen Duff（Nathan Kline Institute / New York University）将使用阿尔茨海默氏病的转基因模型进行行为分析的培训。其他顾问将提供有关神经退行性基础研究（Mattson博士），药物化学（Kozikowski博士）和神经影像学（Fricke博士）乔治敦大学医学中心的专业知识。五年的职业发展计划的目的是：1）为候选人提供临床药物开发方面的深刻了解和背景； 2）在AD小鼠模型的行为分析中改善并扩大了他的研究经验和知识； 3）在使用人类受试者和动物的临床和基础研究中确保道德行为。 该提案的主要研究目标是阐明一种有希望的新型AD治疗方法，“ Abeta固存”。候选人已经证明，可以使用非免疫淀粉样蛋白结合化合物来改变大脑AA。提出的研究将研究AA的池和构象，这些池和构象可能受外围结合化合物的影响，这种化合物的理想结构以及Abeta的血脑屏障运输。